Gain Therapeutics is a startup based in the United States, most recent round Series-c-plus.
Gain Therapeutics is a company headquartered in the United States. Its most recent tracked round is Series-c-plus.
Gain Therapeutics develops allosteric small-molecule therapeutics using AI-supported 3D structural biology and physics-based models. Its lead candidate, GT-02287, is being developed for GBA-linked Parkinson's disease and is in clinical trials.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.